ONO‐7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human study

AIMS: The objectives of this study were to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of ONO‐7684, a novel activated factor XI (FXIa) inhibitor, in healthy subjects. METHODS: This was a first‐in‐human (FIH), randomised, placebo‐contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Beale, Dominic, Dennison, Jeremy, Boyce, Malcolm, Mazzo, Francesca, Honda, Naoki, Smith, Paul, Bruce, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359378/
https://www.ncbi.nlm.nih.gov/pubmed/33450079
http://dx.doi.org/10.1111/bcp.14732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359378/
https://www.ncbi.nlm.nih.gov/pubmed/33450079
http://dx.doi.org/10.1111/bcp.14732

Ejemplares similares